NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea · Delayed Price · Currency is KRW 1,825.00
+420.60 (29.95%)
At close: Jul 21, 2026
NGeneBio Revenue
NGeneBio had revenue of 11.95B KRW in the quarter ending March 31, 2026, with 500.13% growth. This brings the company's revenue in the last twelve months to 31.20B, up 363.66% year-over-year. In the year 2025, NGeneBio had annual revenue of 21.24B with 278.54% growth.
Revenue (ttm)
31.20B
Revenue Growth
+363.66%
P/S Ratio
0.52
Revenue / Employee
n/a
Employees
n/a
Market Cap
16.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.24B | 15.63B | 278.54% |
| Dec 31, 2024 | 5.61B | 1.26B | 28.96% |
| Dec 31, 2023 | 4.35B | -6.67B | -60.51% |
| Dec 31, 2022 | 11.02B | 3.85B | 53.81% |
| Dec 31, 2021 | 7.16B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MOA Life Plus | 10.45B |
| Eutilex.Co.,Ltd | 9.51B |
| Genotech | 7.28B |
| OLIPASS | 5.25B |
| Poongjeon Pharmacy CO.,LTD. | 1.54B |
| Quratis | 1.26B |
| Angiolab | 702.62M |
| Epibiotech | 449.62M |